On Jul. 7, 2020, Regeneron announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense awarded Regeneron a $450 million contract to manufacture and supply REGN-COV2.

REGN-COV2 is Regeneron’s investigational double antibody cocktail that is currently in two Phase 2/3 clinical trials for the treatment of COVID-19 and in a Phase 3 trial for the prevention of COVID-19 infection.